Physician profile
Donna G Mcghee
NPI 1134159221
$4,425.90
in general payments reported to CMS, 2019-2025
7 companies · $2,118 in 2025
The $2,118 reported for 2025 was more than what 99% of Nephrology (Registered Nurse) providers received nationally (typical 2025 total: $522).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.89 · 2022: $316 · 2023: $193 · 2024: $1,715 · 2025: $2,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,354 · Travel and Lodging: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,353.86 |
| Travel and Lodging | $671.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,025.19 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $229.58 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $96.93 | 2022 | |
| Akebia Therapeutics INC | $24.36 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.01 | 2022 | |
| Horizon Therapeutics Plc | $15.16 | 2022 | |
| Aurinia Pharma U.S., INC. | $14.67 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Mcghee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.